Insider Buying: AxoGen, Inc (NASDAQ:AXGN) Director Purchases $217,645.35 in Stock

Share on StockTwits

AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford acquired 15,535 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $14.01 per share, with a total value of $217,645.35. Following the transaction, the director now directly owns 25,098 shares in the company, valued at $351,622.98. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

AXGN stock opened at $14.60 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.70 and a quick ratio of 7.87. The company has a 50 day moving average price of $18.15 and a 200 day moving average price of $19.82. AxoGen, Inc has a fifty-two week low of $11.82 and a fifty-two week high of $46.25. The stock has a market capitalization of $599.82 million, a PE ratio of -27.04 and a beta of 0.18.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. The firm had revenue of $26.70 million during the quarter, compared to analysts’ expectations of $26.77 million. During the same quarter in the previous year, the company posted ($0.09) EPS. AxoGen’s revenue was up 29.7% on a year-over-year basis. As a group, equities analysts expect that AxoGen, Inc will post -0.72 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AXGN. Quantamental Technologies LLC grew its holdings in AxoGen by 108.3% during the 1st quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 744 shares during the period. Cutler Group LP grew its holdings in AxoGen by 120.0% during the 1st quarter. Cutler Group LP now owns 2,200 shares of the medical equipment provider’s stock worth $46,000 after acquiring an additional 1,200 shares during the period. Advisor Group Inc. grew its holdings in AxoGen by 86.3% during the 2nd quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 1,180 shares during the period. Stonebridge Capital Advisors LLC acquired a new stake in AxoGen during the 2nd quarter worth $59,000. Finally, Aperio Group LLC acquired a new stake in AxoGen during the 2nd quarter worth $77,000. Hedge funds and other institutional investors own 87.46% of the company’s stock.

AXGN has been the subject of several research analyst reports. BTIG Research dropped their price objective on shares of AxoGen to $21.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. William Blair cut shares of AxoGen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Canaccord Genuity set a $30.00 price objective on shares of AxoGen and gave the stock a “buy” rating in a research report on Wednesday, August 7th. BidaskClub upgraded shares of AxoGen from a “strong sell” rating to a “sell” rating in a research report on Friday. Finally, ValuEngine upgraded shares of AxoGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $31.00.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

See Also: What is Considered a Good Return on Equity (ROE)?

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
SBA Communications Co.  Shares Sold by Meeder Asset Management Inc.
SBA Communications Co. Shares Sold by Meeder Asset Management Inc.
Cactus Inc  Position Increased by Meeder Asset Management Inc.
Cactus Inc Position Increased by Meeder Asset Management Inc.
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA


© 2006-2019 Ticker Report